Navigation Links
A new class of anti-inflammatory drugs
Date:12/10/2008

This release is available in German.

In the treatment of pain, inflammation and fever, non-steroid anti-rheumatic drugs (NSAR) such as acetylsalicylic acid - more commonly known as Aspirin - or Ibuprofen have always been popular choices. However, had they been tested using today's stringent criteria, many of these drugs would not have passed the clinical trial stage, due to the potential risks and side effects they entail. This suggests the need for more innovative thinking in this area of drug therapy. One such new approach has been developed in Manfred Schubert-Zsilavecz's laboratory at the Goethe University, using chemical substances belonging to the dual mPGES-1/5-LO-Inhibitors. Oliver Werz's group at Tbingen has characterized the substances at the molecular/pharmacological level. Their research results now form the basis of a joint patent application, and a publication in the renowned "Journal of Medicinal Chemistry" (Koeberle et al, J Med Chem (2008), Nov 19. [Epub ahead of print]).

Aspirin and the related NSAR drugs act on the arachidonic acid biosynthesis cascade, which plays a central role in the onset of pain and inflammation. They thus prevent the synthesis of specific prostaglandins, which are essential for vital bodily functions. When the drugs are taken over a long period of time, the unselective inhibition of this essential pathway may result in unwanted side effects on the gastrointestinal tract and the cardiovascular system. As Schubert-Zsilavecz explains: "By comparison, our class of drugs/substances acts on a later stage in the arachidonate cascade, and is more selective. We therefore can expect it to have considerably fewer side effects."

A further advantage of this new class of drugs is that they not only specifically target the biosynthesis of prostaglandin, but also of leukotrienes, which are metabolites in the second important branch of the arachidonate cascade and play a central role in allergic and inflammatory reactions. This double attack promises more effective results for these new substances.

Gerd Geisslinger, Speaker of the LiFF-Initiative and President of the Center for Drug Research, Development and Safety (ZAFES) explains: "This is a most important success for our newly established Lipid Signalling Research Centre, which was established only a short time ago under the LOEWE initiative, funding research in the German state Hesse."


'/>"/>

Contact: Manfred Schubert-Zsilavecz
Schubert-Zsilavecz@pharmchem.uni-frankfurt.de
49-069-798-29339
Goethe University Frankfurt
Source:Eurekalert  

Related medicine news :

1. Popular class of diabetes drugs doubles risk of fractures in women
2. Triple-S Management Corporation Announces Conversion of Class A Shares and Commencement of Class B Stock Repurchase Program
3. Frost & Sullivan Recognises Best-in-Class Innovators
4. On Staying Alives 10th Anniversary, Gym Class Heroes Singer Travis McCoy Named 2009 Foundation Ambassador
5. Scientists at CSHL uncover new RNA processing mechanism and a new class of small RNAs
6. Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff
7. Magistrate Judge Recommends Denial of Class Certification in Funeral Industry Antitrust Litigation
8. Alex Rodriguez, Ryan Howard and Terry Francona to Headline David Ortiz Celebrity Golf Classic
9. Avandias Heart Risk Higher Than Others in Its Class
10. Law Offices of Howard G. Smith Announces Class Action Lawsuit on Behalf of Investors of PharmaNet Development Group, Inc.
11. OmniVision Unveils 1.8 mm, Low Power Medical Sensor With Best-in-Class Low Light Performance
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new class of anti-inflammatory drugs
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: